GSK: progress in HIV prevention for women
(CercleFinance.com) - ViiV Healthcare, the global HIV company, majority owned by GlaxoSmithKline (GSK), with Pfizer and Shionogi Limited also shareholders, has presented interim results of a study of HIV preventive treatment for women.
The results show that long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV infection in women.
The study, which involved 3223 women from seven sub-Saharan African countries (Botswana, Kenya, Malawi, South Africa, Eswatini, Uganda and Zimbabwe), is the first study of long-acting injectable therapy for HIV prevention amongst women.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The results show that long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV infection in women.
The study, which involved 3223 women from seven sub-Saharan African countries (Botswana, Kenya, Malawi, South Africa, Eswatini, Uganda and Zimbabwe), is the first study of long-acting injectable therapy for HIV prevention amongst women.
Copyright (c) 2020 CercleFinance.com. All rights reserved.